Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
November 08 2021 - 8:00AM
Scopus BioPharma Inc. (Nasdaq:
“SCPS”) today announced that, on November 5, 2021, its
2021 Annual Meeting of Stockholders (the “Annual Meeting”) was
adjourned to 11:30 a.m., Eastern time, on Monday, December 20,
2021, without any business being conducted. The adjourned meeting
will be held by means of remote communication and can be accessed
via the following URL: http://www.cesonlineservices.com/scps21_vm.
The adjournment date is pursuant to an understanding between Scopus
and Morris C. Laster, M.D. in connection with Dr. Laster’s pending
litigation against Scopus in the Delaware Court of
Chancery. The record date for the Annual Meeting will
remain August 16, 2021.
The Company continues to take steps to reach
additional understandings with Dr. Laster designed to mitigate the
dispute as well as further expense and disruption of expedited
litigation. In this regard, actions have been taken to transfer
3,500,000 shares of common stock which were in dispute, and to
grant Dr. Laster an irrevocable proxy for such shares.
Scopus continues to solicit votes from its
stockholders with respect to the proposals set forth in Scopus’
proxy statement dated September 16, 2021, as amended on October 26,
2021. Proxies previously submitted in respect of the Annual Meeting
will be voted at the adjourned Annual Meeting unless properly
revoked, and stockholders who have previously submitted a proxy or
otherwise voted and who do not want to change their vote need not
take any action.
Scopus encourages all stockholders who own their
shares as of the close of business on August 16, 2021 who have not
yet voted to do so as soon as possible. Stockholders who have any
questions or require any assistance completing a proxy or voting
instruction form or who do not have the required materials, may
contact Scopus’ proxy solicitor, Morrow Sodali LLC, by calling
collect at (203) 561-6945 or toll-free at (800) 662-5200 or by
emailing SCPS@investor.morrowsodali.com.
About Scopus BioPharma
Scopus BioPharma Inc., both directly and through
subsidiaries, is a biopharmaceutical company developing
transformational therapeutics for serious diseases with significant
unmet medical need.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to risks (including those
set forth in the company’s Form 10-K for the fiscal year ended
December 31, 2020, as amended, filed with the U.S. Securities and
Exchange Commission (“SEC”)) and uncertainties which could cause
actual results to differ from the forward-looking statements. The
company expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company’s
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections. Further,
there can be no assurance that the company will identify and/or
consummate any transaction relating to any additional
technologies.
Contacts
Rodd Leeds/David WaldmanCrescendo
Communications, LLCTel: (212) 671-1020Email:
SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas LeasureReevemarkTel: (212)
433-4600Email: scopus@reevemark.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024